anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for treating inflammatory periodontium diseases. For this purpose, children's Carmolis phytogel for teeth and gums is introduced into pathological pockets and along gingival edge. After this, lazer-phoresis is performed according to a labile technique on an upper and a lower jaw in a segmental manner: 1.8–1.3; 1.3–2.3; 2.3–2.8 – upper jaw segments and 3.8–3.3; 3.3–4.3; 4.3–4.8 – segments of lower jaw. Laser radiation at wave length 662 nm, radiation power 0.4 W, energy density 18 J/cm4 minutes for each segment: 2 minutes from vestibular side and 2 minutes from palatine-lingual side. That is followed by rinsing the oral cavity with solution containing 10–20 Carmolis drops in 0.5 glass of water. Before suppression of manifested inflammation, rinses are performed every 2 hours, then – in 3–4 hours. Therapeutic course of periodontitis is 7 daily procedures, while gingivitis – 5 daily procedures.EFFECT: method provides reducing the length of treatment, achieving stable remission.1 cl, 1 tbl, 2 ex
A medical image diagnosis system according to an embodiment includes a first device, a second device, a communication unit, a first detection unit, a second detection unit, and a control unit. The first device acquires a first signal used for diagnosing a subject, acquires a second signal based on the first signal, and outputs the first signal or the second signal. The second device has a generation unit that generates image data using the first signal or the second signal. The communication unit establishes communication between the second device and the first device and transmits the first signal or the second signal to the second device. The first detection unit detects a diagnostic status from the first device. The second detection unit detects a communication status from the communication unit. The control unit controls at least one of an output from the first device and a communication speed of the communication unit based on the diagnosis condition and the communication condition.
A first aspect of the invention relates to a device for a diagnosis and/or therapy monitoring of inflammatory diseases, such as rheumatoid arthritis. It comprises at least a rest or support device (1) for holding at least one extremity (11) of a person. Thereby, the support device has the task of facilitating the at least one extremity, preferably two extremities, for instance the two hands to be comfortably and immovably placed as long as possible. This support device can be provided with a rest with several accessories, such as indentations, bowl-like recesses, ridges, elastic or non-elastic straps and/or loops, etc.. Furthermore, at least an excitation source (2) for at least partially illuminating one extremity at least with a radiation of defined excitation wavelength. Furthermore, at least an image sensor (3) is incorporated for capturing at least a reference signal from the extremity as well as several signals from the regions of medical interest (ROI) of the extremity (11). Moreover, a device according to the invention comprises a comparator for comparing the reference signal with the signals from the regions of medical interest (ROI).
Severe groups consisted of Severe and Critical Ill of COVID-19. Severe-degree are patients that require high oxygen flow rate with diffuse lung infiltrates. Critical-Ill are COVID-19 patients that suffered shock sepsis or respiratory failure.
Pediatric primary sclerosing cholangitis (PSC) is a rare autoimmune biliary fibrosing disease that leads to significant morbidity, the need for liver transplantation in \~50% of patients, and an increased risk for biliary and colorectal cancers in adulthood. The progression of the biliary disease in children is variable and risk factors associated with a more rapid progression of disease have not been adequately studied. Importantly, pediatric hepatologists have never previously collaborated with inflammatory bowel disease (IBD) specialists to rigorously explore interactions between colonic inflammation and liver disease. New non-invasive imaging modalities to measure fibrosis have not been explored in pediatric PSC. Furthermore, the impact that PSC has on the global functioning of children is not well understood, and likely underappreciated.

The natural history of pediatric PSC is poorly understood. This study aims to determine risk factors, including activity of co-existent IBD, associated with more rapid progression of disease, characterize the impact of PSC on global functioning, define the spectrum and prognostic value of biliary tract disease and liver fibrosis based on novel imaging techniques, and establish a biobank of specimens for future mechanistic studies aimed at discovering biomarkers pertaining to etiology and severity of PSC and novel mechanisms of immunopathogenesis of disease. This comprehensive observational and longitudinal study will delineate unique aspects of the natural history and severity of pediatric PSC and of associated IBD and provide necessary data for future therapeutic trials. It aims to provide a platform to discover and validate circulating and imaging biomarkers, which may serve as surrogate endpoints in future interventional studies.
BACKGROUND: Cold resection of colorectal lesions is widely performed because of its safety and effectiveness; however, it remains uncertain whether adding submucosal injection could improve the efficacy and safety. We aimed to compare cold endoscopic mucosal resection (C-EMR) versus cold snare polypectomy (CSP) for colorectal lesions.
METHODS: We performed a systematic review of randomized controlled trials (RCTs) identified from PubMed, Cochrane Library, and Embase. The primary outcome was complete resection. Secondary outcomes were procedure time, en bloc resection, and adverse events (AEs). Prespecified subgroup analyses based on the size and morphology of the polyps were performed. The random-effects model was used to calculate the pooled risk ratio (RR) and mean difference, with corresponding 95%CIs, for dichotomous and continuous variables, respectively. Heterogeneity was assessed using the Cochran Q test and I 2 statistics.
RESULTS: 7 RCTs were included, comprising 1556 patients, with 2287 polyps analyzed. C-EMR and CSP had similar risk ratios for complete resection (RR 1.02, 95%CI 0.98-1.07), en bloc resection (RR 1.08, 95%CI 0.82-1.41), and AEs (RR 0.74, 95%CI 0.41-1.32). C-EMR had a longer procedure time (mean difference 42.1 seconds, 95%CI 14.5-69.7 seconds). In stratified subgroup analyses, the risk was not statistically different between C-EMR and CSP for complete resection in polyps<10 mm or ≥10 mm, or for complete resection, en bloc resection, and AEs in the two groups among nonpedunculated polyps.
CONCLUSIONS: The findings of this meta-analysis suggest that C-EMR has similar efficacy and safety to CSP, but significantly increases the procedure time.
PROSPERO: CRD42023439605.
After the routine impacted third molar surgery, the kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. Kinesiologic tape will be removed on the second postoperative day, and all sutures on will be removed on 7. postoperative day.
Alirocumab (75 mg every 2 weeks for 6 months) added to statin (Atorvastatin 20-40mg). Anti-platelet aggregation and risk factor management.
The invention discloses a preparation method of traditional Chinese medicine wine for tonifying qi and nourishing yin. According to the method, 60 g of each of gen-seng, medlar, common yam rhizome, Liaoning schisandra chinensis, radix asparagi, radix ophiopogonis, Henan rehmanniae radix, and Henan radix rehmanniae preparata, and 1500 ml of liquor are prepared. The preparation method comprises: cutting the first 8 traditional Chinese medicines, putting into a cloth bag, putting the cloth bag in a container, adding liquor, sealing the container, putting the container in a pot, heating for half an hour with the container being separated from the water, taking the container out, burying in soil for several days to remove fire toxin, taking the container out, and standing for use. The wine has the efficacy of tonifying qi and nourishing yin. The traditional Chinese medicine wine is mainly used for treating symptoms of limb weakness, easy fatigue, waist soreness and leg weakness, distraction, dry mouth, palpitation, dreaminess, vertigo, premature graying of hair and the like caused by deficiency of both qi and yin. The usage of the traditional Chinese medicine wine is oral administration. Ten milliliter of the traditional Chinese medicine wine is taken for each time, and twice a day, morning and night.
Children older than 5 years of age diagnosed with cancer and treated at the Pediatric Hematology/Oncology unit, Hadassah Medical Center will be eligible to the study. The study is designed as a cross-over study, wherein each patient serves as his or her own control, thus all included children should be scheduled to receive at least two identical curses of doxorubicin-containing chemotherapy in which the dose of doxorubicin is at least 60mg/m2 per course. The patients will be assigned to randomly receive curcumin or placebo in the 1st course, with the other regimen administered at the 2nd course. Curcumin will be given as fluid extract (1:1) at a dose of 10 drops, three times a day. Adolescents and young adults will receive the adult recommend dose, i.e. 30 drops, three times a day. Placebo will be given at the same dose. The patients will be taught to rinse the mouth with the medicine and than spit out. The therapy will be given from a day prior to the first day of the cycle for two weeks. A diary kept by the family will record each given dose. Possible side effects associated with the study drug, such as vomiting, nausea, rash, etc., will be recorded. No other adjunctive topical treatment will be used during the study. Adherence will be assessed through subject reports as well as by review of returned medications every cycle collected during the objective assessment site visits. Given the intent-to-treat analysis, all participants will be included irrespective of how much of the study medication was taken.The measurements of study outcome, i.e. OMAS score, WHO mucositis scale and visual analogue pain scale will be done on day 1,7,10,14,21 ± 1 of each chemotherapy cycle. The following data will be recorded in all cycles: duration of neutropenia, the need and length of hospitalization, use and dosage of opioid analgesia, need for total potential nutrition, blood culture positive infection and other mucositis related complications.
PURPOSE: A composition and a functional food containing Circii Radix ethanol extract is provided to treat a patient with renal cancer. CONSTITUTION: A composition for preventing and treating renal cancer contains Circii Radix ethanol extract as an active ingredient, prepared by extracting at 50 Deg. C. for 24 hours. The ethanol is 95% ethanol. The composition contains pharmaceutically acceptable carriers or diluents. The renal is kidney cell cancer. A functional food for preventing renal cancer contains 0.1-5 wt% of the extract as an active ingredient. [Reference numerals] (AA) Relative cell survival rate
The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia. In this study, 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications. Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current, usual antipsychotic medications called perphenazine. An additional 28 patients will be given non-active placebo capsules. Which treatment a patient is given during the study will be determined by chance. Findings from this investigation may directly lead to the improvement of symptoms such as: agitation, hostility, suspiciousness, hallucinations, and unusual thoughts. Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time.
Do not use vardenafil orally disintegrating tablet in patients with moderate or severe hepatic impairment. 

In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects. Vardenafil orally disintegrating tablet can be used in patients with mild hepatic impairment. In volunteers with moderate hepatic impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment. Do not use vardenafil orally disintegrating tablet in patients with moderate to severe hepatic impairment. [See Warnings and Precautions (5.8) and Dosage and Administration (2).]
Nonstructural carbohydrates (NSC) are readily fermentable in the rumen and, are a critical factor while preparing protracted feed for higher animal performance. Four isocaloric and isonitrogenous complete feeds were prepared for this investigation to contain varying levels of nonstructural carbohydrates viz., 40.13 (NSC1), 45.21 (NSC2), 50.00 (NSC3) and 55.85 (NSC4) per cent, respectively. The four isocaloric and isonitrogenous complete feeds were tested in 32 Mecheri ram lambs (around three months of age) in a completely randomised block design (n = 8), and the lambs were fed their respective feed for six months. The study revealed that the increased NSC level in the complete diet increased the body weight and weight gain linearly (P < 0.05). The dietary NSC level affected the dry matter consumption in a quadratic manner (P < 0.05) and the lambs of the NSC4 group consumed significantly (P < 0.05) less DM compared to other dietary groups. The overall average feed conversion efficiency differed significantly (P < 0.05) among dietary groups. The correlation between dietary NSC level and faecal score was quadratic (r2 = 62.7, P < 0.05). The rumen pH, total nitrogen and NH3-N concentration were linearly decreased (P < 0.05) and the molar proportion of total short-chain fatty acids and propionic acid were increased (P < 0.05). The energy loss expressed as methane production was significantly (P < 0.01) lower for the high NSC diet-fed lambs. The lambs fed on a low NSC diet had significantly (P < 0.05) lower carcass weights, dressing percentage and loin eye area. The per cent share of rumen weight in the total fore stomach and the rumen papillae measurements length, width and surface area were significantly (P < 0.05) higher in high NSC diet-fed lambs. Increased levels of NSC in the diet increased (P < 0.05) fat deposition in the internal organs. The saturated fatty acids content in the meat was significantly (P < 0.05) lowered, whereas, the oleic acid and linoleic acid were increased (P < 0.05) as the NSC level increased in the diet. The study revealed that as the level of NSC increased in the complete diet there was a concomitant improvement in the final body weight, ADG and feed efficiency of post-weaned Mecheri lambs. It can therefore be recommended that the complete feed with 50 per cent NSC levels would be optimum to reap maximum returns from fattening Mecheri lambs.
Cannabis is a commonly abused drug whose use cuts across social class, is linked to cognitive impairment, and may be a major contributor to intoxication-related accidents - either alone or with alcohol. However, cannabis intoxication is little studied in relation to driving compared to alcohol. Not only does the current NHTSA Strategic Plan for Behavioral Research prioritize understanding how drugs other than alcohol contribute to traffic crashes, it has recently become more pressing to understand the effects of cannabis because of increasing rates of legalized medical and/or recreational use, that will likely result in more cannabis intoxicated drivers. Social and legal policy will be unable to effectively address the many concerns about driving safety raised by more frequent and widespread use of cannabis without new research to better determine the parameters within which cannabis use does, or does not, increase automobile accident risk. The purpose of this study is to better describe specific, driving-related cognitive impairments caused by acute cannabis intoxication, their persistence over time, underlying functional brain anatomy, and relationship to performance on a state-of the art validated simulated driving task in which the investigators have prior experience. In a randomized, counterbalanced, double-blinded fashion, the investigators will administer two cannabis doses and placebo of smoked cannabis (paced inhalation using a vaporizer) to 48 regular cannabis users and 48 occasional cannabis users on 3 separate occasions. Following cannabis dosing cognitive and driving impairment will be assessed longitudinally for several hours using a combination of fMRI and neuropsychological tests, to clarify relationships between subjective and objective measures of intoxication and of impairment, that include expert assessment of THC and its metabolite levels in blood and saliva. This study takes place in Hartford, Connecticut.
A 36-week multicenter, double-blind, titration/3-period maintenance, cross-over study compared the efficacy of ropinirole extended-release tabletswith the immediate-release formulation of ropinirole tablets(IR) in 161 patients with early phase Parkinson’s disease (Hoehn & Yahr Stages I-III) with limited prior exposure to L-dopa or dopamine agonists. Eligible subjects were randomized (1:1:1:1) to 4 treatment sequences (2 were titrated on ropinirole tabletsIR and 2 on ropinirole extended-release tablets). Titration rate of ropinirole tablets IR was slower than that of the ropinirole extended-release tablets. Patients were titrated, during the 12-week titration period, to their optimal dosage, based upon tolerance and therapeutic response. This was followed by three consecutive 8-week maintenance periods, during which patients were either maintained on the prior formulation or switched to the alternative formulation. All switches were performed overnight by using the approximately equivalent doses of ropinirole. The primary efficacy endpoint was the change of UPDRS motor score within each maintenance period.   
  
  
Patients in all four groups started out with similar UPDRS motor scores (about 21) at baseline. All 4 groups exhibited similar improvement in UPDRS total motor scores from baseline until the completion of the titration phase, with a change in score of about -9 observed for the groups started on ropinirole tabletsIR and of about -10 for the groups started on ropinirole extended-release tablets. No difference was observed between groups when switches were made between identical formulations or between different formulations. This suggests therapeutic dosage equivalence betweenformulations of ropinirole tabletsIR and ropinirole extended-release tabletsformulations.  
  
The optimal daily dose at the end of the titration period for patients on ropinirole tabletsIR was substantially lower (mean 7 mg) compared with the dose at the end of the titration period for patients on ropinirole extended-release tablets(mean 18 mg). In this trial, the marked difference in the final optimal dosages suggests that the higher doses afforded no additional benefit when compared with the lower doses [see Dosage and Administration (2.2)].
This is a single-center, open label, two-arm phase II study of clinical activity of tosedostat in adult patients with MDS who have failed prior hypomethylating agent-based therapy. Arm A is defined as Revised International Prognostic Scoring Systems (IPSS-R) very low, low, and intermediate disease. Arm B is defined as IPSS-R high or very high risk disease. The two arms are separate and will enroll simultaneously. The dose of tosedostat will be 120 mg once a day continuously for each 28 day treatment cycle. Patients will be assessed for disease response, on average, every two cycles as defined in the protocol. If patient has no response as defined by the protocol after two cycles, azacitidine 75 mg/m2 SC or IV for 5 days may be combined with tosedostat, at the investigator's discretion.The primary endpoint the study is to evaluate the safety and efficacy of tosedostat in two groups of patients with myelodysplastic syndrome who have relapsed after or are refractory or intolerant to azacitidine or decitabine. The primary endpoint for patients with IPSS-R very low, low and intermediate disease is transfusion independence and the primary endpoint for patients with high or very high risk disease is overall survival.
FIELD: medicine; cosmetics. SUBSTANCE: remedy has in % by mass: urotropinum 35-40, glycerol 1.0-1.5, perfume additive 0.1-0.2. The rest is water. To prepare the remedy, urotropinum is solved in water. Glycerol and perfume are added later. The remedy is uniform transparent liquid with perfume smell. The remedy is to be kept in storage at 15-25 C. Remedy properties do not change in long term storage. The remedy is applied to freshly washed face skin by means of cotton tampon. Treatment duration is 1-1.5 months. EFFECT: lower production costs; enhanced effectiveness of treatment course. 1 tbl
The invention discloses a bissialoganglioside GD2 affinity peptide and application thereof. The sequence of the affinity peptide YQAF-X is as follows: COOH-Tyr-Gly-Tyr‑His‑X  1  ‑X  2  ‑Arg‑NH  2  . Sialic acid gangliosides are overexpressed in human tumors such as lung cancer, brain cancer, melanoma and the like, and have an influence on EGFR signaling pathways. GANGLIOSIDE can be used as a carbohydrate antigen for the treatment of cancer. The YQAF-X series polypeptide can be combined with tumor cells with high expression of GANGLIOSIDE, and has excellent imaging results on various tumors through in vivo optical imaging and results. The tumor detection reagent and the operation navigation imaging agent prepared based on the YQAF-X series can be better applied to early tumor screening, early tumor diagnosis and operation navigation of tumor operation.